Ketovite Liquid *

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 20 July 2021

File name

ketliq-pl-uk-ie-5-20210625_1626778031.pdf

Reasons for updating

  • Change to section 6 - manufacturer
  • Change to date of revision

Updated on 12 October 2020

File name

ket liq pil_1602504036.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 12 October 2020

File name

ketliq_1602503722.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category:Supply through pharmacy only

Updated on 12 June 2019

File name

Ketliq-pl-uk-ie-2-20190322_1560344623.pdf

Reasons for updating

  • Change to section 6 - marketing authorisation number

Updated on 12 June 2019

File name

Ketliq-spc-ie-1-20190322_1560344540.pdf

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Update to MAH and PA number

Updated on 03 July 2017

File name

PIL_15512_619.pdf

Reasons for updating

  • New PIL for new product

Updated on 03 July 2017

Reasons for updating

  • Change to section 4 - how to report a side effect

Updated on 22 January 2016

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 19 June 2015

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

In section 4.8 (undesirable effects) statement about how to report side effects has been added:$0$0Reporting ofsuspected adverse reactions:$0$0Reporting suspected adverse reactions afterauthorisation of the medicinal product is important. It allows continuedmonitoring of the benefit/risk balance of the medicinal product. Healthcareprofessionals are asked to report any suspected adverse reactions via $0$0HPRA Pharmacovigilance$0$0Earlsfort Terrace $0$0IRL - Dublin 2$0$0Tel: +353 1 6764971$0$0Fax: +353 1 6762517$0$0Website: www.hpra.ie$0$0e-mail: medsafety@hpra.ie$0$0

Updated on 19 June 2015

Reasons for updating

  • New SPC for new product

Legal category:Supply through pharmacy only

Updated on 10 June 2015

Reasons for updating

  • Addition of information on reporting a side effect.

Updated on 05 October 2012

Reasons for updating

  • New SPC for medicines.ie

Legal category:Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

None provided

Updated on 03 October 2012

Reasons for updating

  • New PIL for medicines.ie